



April 24, 2026

To Whom It May Concern,

Company Name: Kubota Pharmaceutical Holdings Co., Ltd.

Title and Name of Representative: Ryo Kubota

Director, Chairman, President, and CEO

(TSE Growth: Code 4596)

Contact: Public Relations & Investor Relations

(TEL : 03-6550-8928 (main))

### Notice Concerning Issuance of New Shares as Restricted Stock Compensation

Kubota Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo; the “Company”) hereby announces that, at a meeting of the Board of Directors held today, it resolved to issue new shares as restricted stock compensation (the “Issuance of New Shares”), as outlined below.

#### 1. Overview of the Issuance of New Shares

- (1) Payment Date: May 8, 2026
- (2) Type and Number of Shares: 1,740,000 shares of common stock of the Company
- (3) Issue Price: JPY 96 per share
- (4) Total Issue Amount: JPY 167,040,000
- (5) Allottee: One Representative Director (1,740,000 shares)

#### 2. Purpose and Reasons for the Issuance

At a meeting of the Board of Directors held on March 18, 2026, the Company resolved to introduce a restricted stock compensation plan (the “Plan”) for its directors (excluding outside directors; hereinafter, the “Eligible Directors”), with the aim of further enhancing their motivation to contribute to the sustainable growth of corporate value and promoting value sharing with shareholders.

At the Annual General Meeting of Shareholders held on April 24, 2026, it was approved that, under the Plan, monetary compensation claims to be contributed as property for acquiring restricted stock (the “Restricted Stock Compensation”) shall be granted to Eligible Directors in an amount not exceeding JPY 200,000 thousand per year, and that the transfer restriction period shall be determined by the Board of Directors.

In addition, the total number of common shares to be newly issued or disposed of under the Plan shall be limited to 1,740,000 shares per year (subject to adjustment within a reasonable range in the event of stock splits, stock consolidations, or similar actions), and the amount to be paid per share shall be determined based on the closing price of the Company’s common shares on the Tokyo Stock Exchange on the business day immediately preceding

the date of the relevant Board resolution (or the closing price on the most recent trading day if no transaction occurs on that date).

Taking into account the purpose of the Plan, the Company's business performance, the scope of responsibilities of the Eligible Directors, and other relevant factors, the Company has decided to grant monetary compensation claims totaling JPY 167,040,000 (the "Monetary Compensation Claims") and 1,740,000 shares of common stock to the Eligible Director in order to further enhance motivation.

In the Issuance of New Shares, pursuant to the Plan, the Eligible Director, who is the allottee, will make an in-kind contribution of all of the Monetary Compensation Claims to the Company and receive an allotment of the Company's common shares (the "Allotted Shares").

An overview of the restricted stock allotment agreement (the "Allotment Agreement") to be entered into between the Company and the Eligible Director is as follows

### 3. Overview of the Allotment Agreement

#### (1) Transfer Restriction Period

The Eligible Director shall not transfer, create a security interest in, or otherwise dispose of the Allotted Shares during the period from May 8, 2026 (the "Payment Date") until the date on which the Eligible Director ceases to hold any position as a director, executive officer, or employee of the Company (the "Restriction Period").

#### (2) Release of Transfer Restrictions

The transfer restrictions on all of the Allotted Shares shall be lifted upon expiration of the Restriction Period, provided that the Eligible Director has continuously served as a board director, executive officer, or employee of the Company during the period from May 8, 2026 to the date of the first Annual General Meeting of Shareholders thereafter (the "Service Period").

In the event of resignation due to death, the transfer restrictions shall be lifted immediately after such resignation.

#### (3) Treatment upon Resignation during Service Period

If the Eligible Director resigns from all positions as a director, corporate auditor, executive officer, or employee of the Company during the Service Period (excluding cases where the Eligible Director is reappointed or reemployed concurrently, or resigns due to death), the Company shall acquire all of the Allotted Shares without consideration upon completion of the necessary book-entry procedures.

#### (4) Management of Shares

During the Restriction Period, the Allotted Shares shall be managed in a dedicated account for restricted stock opened at a securities company designated by the Company, to prevent any transfer, pledge, or other disposition.

#### (5) Treatment upon Organizational Restructuring

If, during the Restriction Period, a merger in which the Company becomes a dissolving company, a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, or any other organizational

restructuring becomes effective, the transfer restrictions on all or part of the Allotted Shares may be lifted on the business day immediately preceding the effective date of such restructuring.

Any shares for which the transfer restrictions have not been lifted at that time shall be acquired by the Company without consideration.

#### 4. Basis for Determination of the Issue Price

The issue price for the Issuance of New Shares has been set at JPY 96 per share, which is the closing price of the Company's common shares on the Tokyo Stock Exchange on April 23, 2026, the business day immediately preceding the date of the Board of Directors resolution, in order to eliminate arbitrariness.

The Company believes that this price reflects the market price immediately prior to the Board resolution date and does not constitute a particularly favorable issuance.

End